Literature DB >> 22767347

Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).

Robert McLinden, Robert Paris, Victoria Polonis, Nicole Close, Zhaohui Su, Cecilia Shikuma, David Margolis, Jerome Kim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22767347      PMCID： PMC3505760          DOI： 10.1097/QAD.0b013e3283550b8e

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  65 in total

1.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

2.  Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

Authors:  C E Hioe; S Xu; P Chigurupati; S Burda; C Williams; M K Gorny; S Zolla-Pazner
Journal:  Int Immunol       Date:  1997-09       Impact factor: 4.823

3.  Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.

Authors:  L J Haddow; C W Wood; J G Ainsworth
Journal:  Int J STD AIDS       Date:  2007-05       Impact factor: 1.359

4.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

5.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Authors:  G M Ortiz; D F Nixon; A Trkola; J Binley; X Jin; S Bonhoeffer; P J Kuebler; S M Donahoe; M A Demoitie; W M Kakimoto; T Ketas; B Clas; J J Heymann; L Zhang; Y Cao; A Hurley; J P Moore; D D Ho; M Markowitz
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

7.  The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

Authors:  J M Binley; A Trkola; T Ketas; D Schiller; B Clas; S Little; D Richman; A Hurley; M Markowitz; J P Moore
Journal:  J Infect Dis       Date:  2000-08-01       Impact factor: 5.226

8.  Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.

Authors:  J H Kim; J R Mascola; S Ratto-Kim; T C VanCott; L Loomis-Price; J H Cox; N L Michael; L Jagodzinski; C Hawkes; D Mayers; B L Gilliam; D C Birx; M L Robb
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-20       Impact factor: 2.205

9.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype.

Authors:  J R Mascola; J Louwagie; F E McCutchan; C L Fischer; P A Hegerich; K F Wagner; A K Fowler; J G McNeil; D S Burke
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226
View more
  5 in total

1.  Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.

Authors:  Kai Yang; Jie Lan; Nicole Shepherd; Ningjie Hu; Yanyan Xing; Daniel Byrd; Tohti Amet; Corlin Jewell; Samir Gupta; Carole Kounga; Jimin Gao; Qigui Yu
Journal:  J Virol       Date:  2015-07-01       Impact factor: 5.103

Review 2.  Practical considerations in gene therapy for HIV cure.

Authors:  Rodica Stan; John A Zaia
Journal:  Curr HIV/AIDS Rep       Date:  2014-03       Impact factor: 5.071

3.  Understanding the Determinants of BnAb Induction in Acute HCV Infection.

Authors:  Alexander P Underwood; Melanie R Walker; Nicholas A Brasher; Auda A Eltahla; Lisa Maher; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Viruses       Date:  2018-11-21       Impact factor: 5.048

Review 4.  Antiretroviral therapy interruptions: impact on HIV treatment and transmission.

Authors:  Gueorgui Dubrocq; Natella Rakhmanina
Journal:  HIV AIDS (Auckl)       Date:  2018-06-13

5.  T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.

Authors:  Prabhu S Arunachalam; Tysheena P Charles; Vineet Joag; Venkata S Bollimpelli; Madeleine K D Scott; Florian Wimmers; Samantha L Burton; Celia C Labranche; Caroline Petitdemange; Sailaja Gangadhara; Tiffany M Styles; Clare F Quarnstrom; Korey A Walter; Thomas J Ketas; Traci Legere; Pradeep Babu Jagadeesh Reddy; Sudhir Pai Kasturi; Anthony Tsai; Bertrand Z Yeung; Shakti Gupta; Mark Tomai; John Vasilakos; George M Shaw; Chil-Yong Kang; John P Moore; Shankar Subramaniam; Purvesh Khatri; David Montefiori; Pamela A Kozlowski; Cynthia A Derdeyn; Eric Hunter; David Masopust; Rama R Amara; Bali Pulendran
Journal:  Nat Med       Date:  2020-05-11       Impact factor: 53.440
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.